Novel PCDH12 pathogenic missense variants cause neurodevelopmental disorders with ocular malformation

This study identifies novel pathogenic missense variants in the PCDH12 gene that cause neurodevelopmental disorders with ocular malformations by disrupting both homophilic and heterophilic adhesion mechanisms, thereby expanding the known genotype-phenotype spectrum beyond previously characterized loss-of-function mutations.

The Gist

The Big Picture: A Broken "Glue" Protein

Imagine your brain is a massive, bustling city. For the city to function, the buildings (neurons) need to be connected by roads and bridges so messages can travel between them.

PCDH12 is like a specialized super-glue that cells use to stick to each other and build these roads. It's a protein found on the surface of cells, acting like a handshake mechanism. When two cells meet, their PCDH12 proteins reach out, grab hands, and say, "We belong together." This helps build the brain's wiring and also helps form the blood vessels in the eyes.

Usually, when scientists find people with brain and eye problems caused by PCDH12, they find "broken" glue that is missing entirely (like a factory that stopped making glue). But this new study found something different: people with "sticky" glue that is chemically altered.

The Discovery: Two Families, Four "Typos"

The researchers looked at two families with children who had severe developmental delays, seizures, behavioral issues, and eye problems.

Instead of finding missing glue, they found four specific "typos" in the instructions for making the PCDH12 glue.

• Two typos happened on the outside of the glue (the part that reaches out to grab other cells).
• Two typos happened on the inside of the glue (the part that anchors it to the cell's skeleton).

Crucially, every sick child had one typo on the outside AND one typo on the inside. They didn't have just one; they had a "double whammy" (compound heterozygous).

The Experiment: Testing the Glue

The scientists wanted to know: Does this altered glue still work?

1. The "Handshake" Test (Adhesion)
They made beads coated with the "good" glue and beads coated with the "bad" glue.

• Good Glue: When they mixed the good beads with calcium (a trigger), they instantly stuck together in big clumps.
• Bad Glue (Outside Typos): The beads with the outside typos barely stuck at all. They were like hands that were slippery or misshapen. They couldn't hold on.
• The Surprise: Even though the "bad" glue was on the outside, it didn't just sit there; it actually made it harder for the "good" glue to work properly when they were mixed together. It was like having a slippery hand in a handshake that made the whole grip weaker.

2. The "Anchor" Test (Cytoskeleton)
They checked if the inside typos broke the anchor that holds the glue to the cell's skeleton.

• Result: Surprisingly, the anchor seemed fine. The glue was still attached to the cell. The problem wasn't that it fell off; it was that it couldn't grab its neighbor effectively.

3. The "New Neighbor" Test (PCDH19 Interaction)
The scientists discovered that PCDH12 also likes to shake hands with a different protein called PCDH19 (which is famous for causing epilepsy).

• Result: The "bad" outside glue (the typos) couldn't hold onto PCDH19 very well. This is a big deal because it suggests that when PCDH12 breaks, it might also mess up the brain circuits involving PCDH19, potentially explaining why some patients have seizures.

The Eye Connection: Why the Eyes?

You might wonder, "Why do these kids have eye problems?"

Think of the brain and the eye as cousins that develop at the same time using the same blueprints. PCDH12 is needed to build the tiny blood vessels in the retina (the back of the eye).

• In some families, the "glue" failure caused the blood vessels to grow weirdly (like a garden hose with kinks).
• In the second family, the "glue" failure caused the eye itself to not grow big enough (microphthalmia) or the cornea to turn cloudy (sclerocornea).

It's like if the construction crew for a house (the brain) and the landscaping crew for the garden (the eye) both used the same faulty cement. Both the house and the garden would end up with structural problems.

The "Double Whammy" Theory

Here is the most important takeaway: One typo isn't enough to break the system, but two are.

• If you only have the "outside" typo, the glue is weak, but maybe the cell can cope.
• If you only have the "inside" typo, the anchor is shaky, but maybe the glue can still grab.
• But when you have BOTH: The glue is slippery and the anchor is slightly off. The system collapses. This explains why the parents (who only have one typo) are healthy, but the children (who have two) are very sick.

Summary

This study is like finding a new type of broken lock. We knew that if the lock was missing, the door wouldn't open. Now we know that if the lock is twisted (outside typo) and the keyhole is slightly misaligned (inside typo), the door still won't open, even if the lock is technically there.

This helps doctors understand that for some patients, the problem isn't just "no protein," but "broken protein." It also highlights that the brain and eyes are deeply connected, and fixing one might require understanding how they both rely on this specific molecular glue.

Technical Summary

1. Problem Statement

• Background: Protocadherin-12 (PCDH12) is a cell-adhesion molecule critical for neuronal connectivity and vascular development. Bi-allelic loss-of-function (LoF) variants (nonsense, frameshift) in PCDH12 are known to cause neurodevelopmental disorders (NDDs), including diencephalic-mesencephalic junction dysplasia, cerebral palsy, and cerebellar ataxia, often accompanied by ocular abnormalities.
• The Gap: While LoF variants are well-characterized, the clinical expressivity of PCDH12-related disorders is highly variable, even among individuals with identical variants. Furthermore, the pathogenic mechanisms of non-truncating missense variants in PCDH12 had not been previously reported or functionally characterized. It was unclear whether missense variants cause disease via loss of function (LoF) or gain of function, and how specific protein domains (extracellular vs. intracellular) contribute to the phenotype.
• Objective: To identify and functionally characterize novel compound heterozygous missense variants in PCDH12 in patients with NDDs and ocular malformations, and to determine their molecular impact on protein stability, adhesion, and interaction networks.

2. Methodology

The study employed a multi-disciplinary approach combining clinical genetics, bioinformatics, and cell biology:

• Clinical Cohort & Genetics:

  • Identified three affected individuals from two unrelated families (Family 3: one proband; Family 4: two siblings) via GeneMatcher and clinical clinics.
  • Performed trio or whole-exome sequencing (WES) to identify variants.
  • Validated variants via Sanger sequencing and confirmed co-segregation within families.
  • Assessed pathogenicity using in silico predictors (PolyPhen-2, SIFT, CADD, etc.) and structural modeling (AlphaFold2, ESMFold, DDMut).

• In Vitro Functional Assays:

  • Cell Lines: HEK293T and HeLa cells were transfected with wild-type (WT) and mutant PCDH12 constructs (fused to mCherry/eGFP or Fc domains).
  • Protein Expression & Localization: Western blotting and immunofluorescence were used to assess protein stability, abundance, and subcellular localization.
  • Adhesion Assays: A bead aggregation assay using Fc-fused extracellular domains (EC) of PCDH12 (WT and mutants) to measure homophilic adhesion capabilities in the presence of calcium.
  • Cytoskeleton Analysis: Immunofluorescence staining for F-actin and WAVE1 to determine if variants disrupted the link between PCDH12 and the actin cytoskeleton (via the WRC binding motif).
  • Protein-Protein Interactions: Co-immunoprecipitation (Co-IP) assays to investigate:
    1. Homophilic binding (PCDH12-PCDH12).
    2. Heterophilic binding between PCDH12 and PCDH19 (an epilepsy-associated protocadherin).
  • RNA Analysis: Gene transactivation in patient fibroblasts followed by RNA-seq to assess nonsense-mediated decay (NMD) and splicing of truncating variants.

3. Key Contributions & Results

A. Clinical and Genetic Findings

• Novel Variants: The study identified the first non-truncating, compound heterozygous missense variants in PCDH12 associated with NDDs.
  • Family 3: c.1742T>G (p.Val581Gly) [Extracellular, EC6] and c.3445G>A (p.Asp1149Asn) [Intracellular].
  • Family 4: c.1861_1862del/insCA (p.Ile621His) [Extracellular, EC6] and c.3370C>T (p.Arg1124Cys) [Intracellular].
• Phenotypes: All three patients presented with NDDs (intellectual disability, developmental delay, seizures, microcephaly in one case) and ocular malformations.
  • Family 3: Microcephaly, seizures, optic atrophy, high myopia.
  • Family 4: Severe structural eye defects (bilateral microphthalmia/sclerocornea in the sister; unilateral in the brother) and severe behavioral disorders (autism, aggression).
• Phenotypic Variability: The study highlights that missense variants can produce phenotypes similar to LoF variants, suggesting a loss-of-function mechanism, but with distinct ocular presentations (structural malformations vs. retinal vascular issues seen in LoF).

B. Structural and Stability Analysis

• Destabilization: In silico modeling (DDMut) predicted that the extracellular variants (p.Val581Gly, p.Ile621His) are highly destabilizing to the protein structure (ΔΔG ~ -2.9 kcal/mol). These residues are located in the EC6 domain, crucial for the hydrophobic core of the beta-barrel.
• Intracellular Variants: The intracellular variants (p.Arg1124Cys, p.Asp1149Asn) showed mild destabilization predictions, though structural modeling of this region is less accurate.
• Expression: Western blots confirmed that all four variants are expressed at levels comparable to WT in HEK293T and HeLa cells, ruling out gross protein degradation as the primary mechanism.

C. Functional Consequences

• Impaired Homophilic Adhesion: Bead aggregation assays revealed that the extracellular variants (p.Val581Gly and p.Ile621His) significantly reduced homophilic adhesion compared to WT.
  • WT-PCDH12EC formed large aggregates (>5 µm²) in ~66% of beads.
  • Mutant variants showed aggregation rates similar to negative controls (~40%).
  • Heterozygosity Effect: Mixing WT and mutant beads showed that the presence of a mutant copy did not completely abolish WT adhesion, but the mutant copy itself was non-functional.
• Cytoskeleton Interaction: Contrary to previous hypotheses regarding the WRC/actin link, the study found no significant alteration in F-actin organization or WAVE1 localization in cells expressing any of the variants. This suggests the cytoskeletal defect is not the primary driver in this specific cellular model.
• Heterophilic Interaction with PCDH19:
  • Co-IP confirmed a direct interaction between PCDH12 and the extracellular domain of PCDH19.
  • Key Finding: The extracellular missense variants (p.Val581Gly, p.Ile621His) reduced the stability/expression of PCDH19 and decreased the binding affinity between PCDH12 and PCDH19. Intracellular variants did not affect this interaction.

4. Significance and Implications

• Mechanistic Insight: The study establishes that specific missense variants in PCDH12 cause disease through a loss-of-function mechanism driven by structural destabilization and impaired cell adhesion, rather than protein absence.
• Domain-Specific Effects: It distinguishes the roles of PCDH12 domains:
  • Extracellular (EC6): Critical for structural stability and homophilic/heterophilic adhesion. Mutations here disrupt the adhesion network and destabilize interacting partners (PCDH19).
  • Intracellular: While predicted to be less destabilizing, their presence in compound heterozygosity with extracellular variants likely acts synergistically to push the phenotype toward severe NDD.
• Phenotypic Expansion: The discovery of severe structural ocular malformations (microphthalmia, sclerocornea) in addition to retinal vascular issues expands the known clinical spectrum of PCDH12 disorders. This suggests PCDH12 is vital for early eye morphogenesis (lens/retina) as well as vascular maintenance.
• Genotype-Phenotype Correlation: The study provides a potential explanation for the variable expressivity of PCDH12 disorders. The specific combination of extracellular (adhesion-defective) and intracellular variants, along with potential heterophilic interactions with PCDH19 (linked to epilepsy), may dictate the severity of neurological and ocular outcomes.
• Clinical Relevance: These findings support the classification of these missense variants as pathogenic and highlight the need to screen for PCDH12 in patients with unexplained NDDs and ocular anomalies, even in the absence of truncating mutations.

Conclusion

This paper provides the first functional evidence that non-truncating PCDH12 missense variants cause neurodevelopmental and ocular disorders by destabilizing the protein structure and impairing cell-adhesion functions. The study underscores the complexity of PCDH12 biology, revealing a critical interplay between homophilic adhesion, heterophilic interactions with PCDH19, and the specific contributions of extracellular versus intracellular domains to the disease phenotype.